Literature DB >> 23674677

Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs.

John Hines1, Jonathan D Gough, Timothy W Corson, Craig M Crews.   

Abstract

Posttranslational knockdown of a specific protein is an attractive approach for examining its function within a system. Here we introduce phospho-dependent proteolysis targeting chimeras (phosphoPROTACs), a method to couple the conditional degradation of targeted proteins to the activation state of particular kinase-signaling pathways. We generated two phosphoPROTACs that couple the tyrosine phosphorylation sequences of either the nerve growth factor receptor, TrkA (tropomyosin receptor kinase A), or the neuregulin receptor, ErbB3 (erythroblastosis oncogene B3), with a peptide ligand for the E3 ubiquitin ligase von Hippel Lindau protein. These phosphoPROTACs recruit either the neurotrophic signaling effector fibroblast growth factor receptor substrate 2α or the survival-promoting phosphatidylinositol-3-kinase, respectively, to be ubiquitinated and degraded upon activation of specific receptor tyrosine kinases and phosphorylation of the phosphoPROTACs. We demonstrate the ability of these phosphoPROTACs to suppress the short- and long-term effects of their respective activating receptor tyrosine kinase pathways both in vitro and in vivo. In addition, we show that activation of phosphoPROTACs is entirely dependent on their kinase-mediated phosphorylation, as phenylalanine-containing null variants are inactive. Furthermore, stimulation of unrelated growth factor receptors does not induce target protein knockdown. Although comparable in efficiency to RNAi, this approach has the added advantage of providing a degree of temporal and dosing control as well as cell-type selectivity unavailable using nucleic acid-based strategies. By varying the autophosphorylation sequence of a phosphoPROTAC, it is conceivable that other receptor tyrosine kinase/effector pairings could be similarly exploited to achieve other biological effects.

Entities:  

Keywords:  SH2 domain; protein degradation; signal transduction

Mesh:

Substances:

Year:  2013        PMID: 23674677      PMCID: PMC3670320          DOI: 10.1073/pnas.1217206110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  SH2 domains recognize contextual peptide sequence information to determine selectivity.

Authors:  Bernard A Liu; Karl Jablonowski; Eshana E Shah; Brett W Engelmann; Richard B Jones; Piers D Nash
Journal:  Mol Cell Proteomics       Date:  2010-07-13       Impact factor: 5.911

Review 2.  Chemical approaches to controlling intracellular protein degradation.

Authors:  John S Schneekloth; Craig M Crews
Journal:  Chembiochem       Date:  2005-01       Impact factor: 3.164

3.  A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway.

Authors:  H Kouhara; Y R Hadari; T Spivak-Kroizman; J Schilling; D Bar-Sagi; I Lax; J Schlessinger
Journal:  Cell       Date:  1997-05-30       Impact factor: 41.582

4.  FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors.

Authors:  S H Ong; G R Guy; Y R Hadari; S Laks; N Gotoh; J Schlessinger; I Lax
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

5.  The signaling adapter FRS-2 competes with Shc for binding to the nerve growth factor receptor TrkA. A model for discriminating proliferation and differentiation.

Authors:  S O Meakin; J I MacDonald; E A Gryz; C J Kubu; J M Verdi
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

6.  Neurite outgrowth in PC12 cells. Distinguishing the roles of ubiquitylation and ubiquitin-dependent proteolysis.

Authors:  M Obin; E Mesco; X Gong; A L Haas; J Joseph; A Taylor
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

7.  Nerve growth factor enhances the synthesis, phosphorylation, and metabolic stability of neurofilament proteins in PC12 cells.

Authors:  M H Lindenbaum; S Carbonetto; W E Mushynski
Journal:  J Biol Chem       Date:  1987-01-15       Impact factor: 5.157

8.  Autophosphorylation of activation loop tyrosines regulates signaling by the TRK nerve growth factor receptor.

Authors:  M E Cunningham; R M Stephens; D R Kaplan; L A Greene
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

Review 9.  Design and Applications of Bifunctional Small Molecules: Why Two Heads Are Better Than One.

Authors:  Timothy W Corson; Nicholas Aberle; Craig M Crews
Journal:  ACS Chem Biol       Date:  2008-11-21       Impact factor: 5.100

10.  Tat-mediated delivery of heterologous proteins into cells.

Authors:  S Fawell; J Seery; Y Daikh; C Moore; L L Chen; B Pepinsky; J Barsoum
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 12.779

View more
  42 in total

1.  Small molecule target identification using photo-affinity chromatography.

Authors:  Seung-Yong Seo; Timothy W Corson
Journal:  Methods Enzymol       Date:  2019-03-15       Impact factor: 1.600

Review 2.  Protein-Catalyzed Capture Agents.

Authors:  Heather D Agnew; Matthew B Coppock; Matthew N Idso; Bert T Lai; JingXin Liang; Amy M McCarthy-Torrens; Carmen M Warren; James R Heath
Journal:  Chem Rev       Date:  2019-03-06       Impact factor: 60.622

Review 3.  Targeted Protein Degradation by Small Molecules.

Authors:  Daniel P Bondeson; Craig M Crews
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016-10-12       Impact factor: 13.820

4.  DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation.

Authors:  Georg E Winter; Dennis L Buckley; Joshiawa Paulk; Justin M Roberts; Amanda Souza; Sirano Dhe-Paganon; James E Bradner
Journal:  Science       Date:  2015-05-21       Impact factor: 47.728

5.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

Authors:  George M Burslem; Blake E Smith; Ashton C Lai; Saul Jaime-Figueroa; Daniel C McQuaid; Daniel P Bondeson; Momar Toure; Hanqing Dong; Yimin Qian; Jing Wang; Andrew P Crew; John Hines; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

Review 6.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 7.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

Review 8.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

9.  Catalytic in vivo protein knockdown by small-molecule PROTACs.

Authors:  Daniel P Bondeson; Alina Mares; Ian E D Smith; Eunhwa Ko; Sebastien Campos; Afjal H Miah; Katie E Mulholland; Natasha Routly; Dennis L Buckley; Jeffrey L Gustafson; Nico Zinn; Paola Grandi; Satoko Shimamura; Giovanna Bergamini; Maria Faelth-Savitski; Marcus Bantscheff; Carly Cox; Deborah A Gordon; Ryan R Willard; John J Flanagan; Linda N Casillas; Bartholomew J Votta; Willem den Besten; Kristoffer Famm; Laurens Kruidenier; Paul S Carter; John D Harling; Ian Churcher; Craig M Crews
Journal:  Nat Chem Biol       Date:  2015-06-10       Impact factor: 15.040

10.  HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins.

Authors:  Dennis L Buckley; Kanak Raina; Nicole Darricarrere; John Hines; Jeffrey L Gustafson; Ian E Smith; Afjal H Miah; John D Harling; Craig M Crews
Journal:  ACS Chem Biol       Date:  2015-06-23       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.